

**DESCRIPTION**

<b>Source</b>	Human embryonic kidney cell, HEK293-derived human PD-L1/B7-H1 protein		
	Human B7-H1 (Phe19-Thr239) Accession # Q9NZQ7	HHHHHH	Avi-tag
	N-terminus		C-terminus
<b>N-terminal Sequence</b>	Phe19		
<b>Analysis</b>			
<b>Structure / Form</b>	Biotinylated via Avi-tag		
<b>Predicted Molecular Mass</b>	28 kDa		

**SPECIFICATIONS**


<b>SDS-PAGE</b>	35-41 kDa, reducing conditions
<b>Activity</b>	Measured by its binding ability in a functional ELISA. When Recombinant Human PD-1 Fc Chimera (Catalog # 1086-PD) is immobilized at 2 µg/mL (100 µL/well), Biotinylated Recombinant Human PD-L1 His-tag Avi-tag protein binds with an ED <sub>50</sub> of 2-12 µg/mL.
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the protein by the LAL method.
<b>Purity</b>	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 500 µg/mL in PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<p><b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b></p> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 3 months, ≤ -20 °C under sterile conditions after reconstitution.</li> </ul>


**DATA**

**Binding Activity**



When Recombinant Human PD-1 Fc Chimera (Catalog # 1086-PD) is immobilized at 2 µg/mL, Biotinylated Recombinant Human PD-L1 His-tag Avi-tag protein binds with an ED<sub>50</sub> of 2-12 µg/mL.

**SDS-PAGE**



2 µg/lane of Biotinylated Recombinant Human PD-L1/B7-H1 His Tag Avi Tag was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 35-41 kDa.

## BACKGROUND

B7-H1, also known as PD-L1 and CD274, is an approximately 65-kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature human B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (2). Within the ECD, human B7-H1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (3). B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (4-7), keratinocytes (8, 9), endothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (11, 12). B7-H1 binds to T cell B7-1/CD80 and PD-1 (7, 8, 12-15). It suppresses T cell activation and proliferation (5, 8, 14, 16) and induces the apoptosis of activated T cells (11). It plays a role in the development of immune tolerance by promoting T cell anergy (7, 14) and enhancing regulatory T cell development (16). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (5, 10) and inhibits the development of Th17 cells (16). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (6, 9, 12, 15).

## References:

1. Ceeraz, S. *et al.* (2013) *Trends Immunol.* **34**:556.
2. Dong, H. *et al.* (1999) *Nat. Med.* **5**:1365.
3. Frigola, X. *et al.* (2011) *Clin. Cancer Res.* **17**:1915.
4. Tamura, H. *et al.* (2001) *Blood* **97**:1809.
5. Chen, L. *et al.* (2007) *J. Immunol.* **178**:6634.
6. Kuang, D.-M. *et al.* (2014) *J. Clin. Invest.* **124**:4657.
7. Tsushima, F. *et al.* (2007) *Blood* **110**:180.
8. Mazanet, M.M. and C.C.W. Hughes (2002) *J. Immunol.* **169**:3581.
9. Cao, Y. *et al.* (2010) *Cancer Res.* **71**:1235.
10. Scanduzzi, L. *et al.* (2014) *Cell Rep.* **6**:625.
11. Dong, H. *et al.* (2002) *Nat. Med.* **8**:793.
12. Azuma, T. *et al.* (2008) *Blood* **111**:3635.
13. Butte, M.J. *et al.* (2008) *Mol. Immunol.* **45**:3567.
14. Park, J.-J. *et al.* (2010) *Blood* **116**:1291.
15. Ritprajak, P. *et al.* (2010) *J. Immunol.* **184**:4918.
16. Herold, M. *et al.* (2015) *J. Immunol.* **195**:3584.